Skip to content
Review Open access

Immune checkpoint inhibitor-based therapy in gynecologic clear cell carcinoma: A systematic review and meta-analysis

Sep 2026 · Eurasian Journal of Medicine and Oncology · 0 citations

Abstract

Introduction: Gynecologic clear cell carcinoma (CCC) is an uncommon histologic entity for which therapeutic options remain limited, and the clinical activity of immune checkpoint inhibitor (ICI)-based treatment has not been clearly defined. Objective: To synthesize the available evidence on efficacy and safety of ICI-containing regimens in gynecologic CCC. Methods: We performed a Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020-guided systematic review and meta-analysis. PubMed, Web of Science, and Embase were searched for peer-reviewed full-text studies published between January 2016 and February 7, 2026 that investigated ICI-based treatment in gynecologic CCC. Studies were eligible if they included objective response rate (ORR), grade ≥ 3 adverse events (AEs), or both. Pooled proportions were obtained through a binomial random-intercept generalized linear mixed model (GLMM); subgroup and sensitivity analyses were exploratory. Results: Six studies included 181 patients in the efficacy analysis and 189 in the safety analysis. The GLMM estimate for ORR was 0.31 (95% confidence interval [CI], 0.20–0.44; I2 = 66.1%), and the 95% prediction interval was 0.06–0.74. By treatment strategy, exploratory pooled ORRs were 0.17 (95% CI: 0.07–0.39) for ICI monotherapy and 0.42 (95% CI: 0.32–0.52) for combination regimens. The conventional subgroup comparison yielded p = 0.040, whereas Knapp–Hartung-adjusted meta-regression yielded p=0.094. For study-defined grade ≥ 3 AEs, the pooled proportion was 0.24 (95% CI: 0.12–0.40; I2=78.1%) with a 95% prediction interval of 0.02–0.81. Corresponding exploratory safety estimates were 0.31 for combination therapy and 0.15 for monotherapy (pbetween = 0.160). Conclusion: ICI-containing therapy shows variable antitumor activity across gynecologic CCC cohorts. Combination cohorts had numerically higher response and severe-toxicity rates, but these nonrandomized across-study contrasts were sensitive to small-sample adjustment and confounded by differences in regimens and populations. Overall certainty of the evidence was very low.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.